Related Experiment Videos
Hormone receptors and breast cancer--an occasional survey
Abstract:
Hormone receptors are proteins, localised in the membrane, cytosol, mitochondrion or nucleus of target cells; binding of hormone to the receptor leads to alterations in intracellular activity or growth. The development of antagonists which competitively bind to receptor sites has been used clinically to block, for example, the action of androgen, histamine, adrenaline and oestrogen. In patients with breast cancer, measurements of hormone receptor activity are valuable (1) in predicting which patients with advanced disease will respond to endocrine therapy, (2) as an additional independent guide to the patients' prognosis. The anti-oestrogen, tamoxifen has few side-effects and is therefore particularly useful in the treatment of advanced disease. In addition, two trials, performed in the USA, suggest that this receptor-blocker may be valuable in the adjuvant treatment of early disease. In the UK, further trials are underway to confirm this and to assess the relationship of hormone receptor status in the primary tumour to benefit from treatment.
Insights
Hormone receptor activity measurement is crucial for predicting breast cancer patient response to endocrine therapy and prognosis. Anti-oestrogen drugs like tamoxifen show promise in both advanced and early-stage disease treatment.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Hormone receptors are proteins that mediate cellular responses to hormones.
- Hormone receptor antagonists competitively bind to receptor sites, blocking hormone action.
- Measurement of hormone receptor activity is vital in breast cancer management.
Purpose of the Study:
- To evaluate the clinical utility of hormone receptor activity measurements in breast cancer.
- To assess the efficacy of endocrine therapy and anti-oestrogen drugs in breast cancer patients.
- To explore the prognostic value of hormone receptor status in early and advanced breast cancer.
Main Methods:
- Analysis of hormone receptor activity in target cells.
- Clinical trials investigating the use of hormone receptor antagonists, such as tamoxifen.
- Prognostic assessment based on hormone receptor status in primary tumors.
Main Results:
- Hormone receptor activity measurement predicts response to endocrine therapy in advanced breast cancer.
- Tamoxifen, an anti-oestrogen, is effective with few side effects in advanced disease.
- US trials suggest tamoxifen's value in adjuvant treatment for early breast cancer.
Conclusions:
- Hormone receptor status is a key factor in guiding breast cancer treatment decisions.
- Endocrine therapy and drugs like tamoxifen are valuable in managing breast cancer.
- Ongoing UK trials aim to further elucidate the role of hormone receptor status in treatment benefit.